Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 17 and set a price target of ...
The U.S. Department of Agriculture is urging poultry producers to intensify bird flu testing. The WHO is advocating for U.S.
We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...
President-elect Donald Trump says he “most likely” will give TikTok 90 more days to work out a deal that would allow the ...
You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...
Wall Street started higher ahead of Trump's inauguration on Monday. Investors expect a flurry of executive orders, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback